Clear cell renal cell carcinoma metastasizing to the thyroid gland: a case report
Frontiers in Oncology · 13.04.2026 · 16
DOI: 10.3389/fonc.2026.1752093 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 13.04.2026. Verfasst von Zhengshi Xia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metastatic tumors of the thyroid gland are rare in clinical practice. Clear cell renal cell carcinoma (ccRCC) is the most common primary site among metastatic thyroid carcinomas, accounting for 12% to 34% of all secondary thyroid tumors. Most secondary thyroid cancers have a poorer prognosis than primary papillary thyroid carcinoma. Therefore, the diagnosis and treatment of secondary thyroid tumors deserve attention. The diagnosis and treatment of secondary thyroid carcinoma pose significant challenges. We herein report a case of clear cell renal cell carcinoma metastasizing to the thyroid gland.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zitieren
APA
Xia, Z., Zhao, Z., Sun, P., Xu, P., & Li, J. (2026). Clear cell renal cell carcinoma metastasizing to the thyroid gland: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1752093
Vancouver
Xia Z, Zhao Z, Sun P, Xu P, Li J. Clear cell renal cell carcinoma metastasizing to the thyroid gland: a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1752093
BibTeX
@article{Xia2026,
author = {Xia, Zhengshi and Zhao, Zuzhi and Sun, Peng and Xu, Pengfei and Li, Jianhua},
title = {Clear cell renal cell carcinoma metastasizing to the thyroid gland: a case report},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1752093}
}
EUVIMED